PMID- 31143179
OWN - NLM
STAT- MEDLINE
DCOM- 20200930
LR  - 20200930
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 10
DP  - 2019
TI  - Beyond cDC1: Emerging Roles of DC Crosstalk in Cancer Immunity.
PG  - 1014
LID - 10.3389/fimmu.2019.01014 [doi]
LID - 1014
AB  - Dendritic cells (DCs) efficiently process and present antigens to T cells, and by 
      integrating environmental signals, link innate and adaptive immunity. DCs also 
      control the balance between tolerance and immunity, and are required for T-cell 
      mediated anti-tumor immunity. One subset of classical DCs, cDC1, are particularly 
      important for eliciting CD8 T cells that can kill tumor cells. cDC1s are superior 
      in antigen cross-presentation, a process of presenting exogenous antigens on MHC 
      class I to activate CD8(+) T cells. Tumor-associated cDC1s can transport tumor 
      antigen to the draining lymph node and cross-present tumor antigens, resulting in 
      priming and activation of cytotoxic T cells. Although cross-presenting cDC1s are 
      critical for eliciting anti-tumor T cell responses, the role and importance of 
      other DC subsets in anti-tumor immunity is not as well-characterized. Recent 
      literature in other contexts suggests that critical crosstalk between DC subsets 
      can significantly alter biological outcomes, and these DC interactions likely 
      also contribute significantly to tumor-specific immune responses. Therefore, 
      antigen presentation by cDC1s may be necessary but not sufficient for maximal 
      immune responses against cancer. Here, we discuss recent advances in the 
      understanding of DC subset interactions to maximize anti-tumor immunity, and 
      propose that such interactions should be considered for the development of better 
      DC-targeted immunotherapies.
FAU - Noubade, Rajkumar
AU  - Noubade R
AD  - Department of Inflammation and Oncology, Amgen Research, Amgen Inc., South San 
      Francisco, CA, United States.
FAU - Majri-Morrison, Sonia
AU  - Majri-Morrison S
AD  - Department of Inflammation and Oncology, Amgen Research, Amgen Inc., South San 
      Francisco, CA, United States.
FAU - Tarbell, Kristin V
AU  - Tarbell KV
AD  - Department of Inflammation and Oncology, Amgen Research, Amgen Inc., South San 
      Francisco, CA, United States.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20190509
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Cytokines)
SB  - IM
MH  - Animals
MH  - Antigen Presentation
MH  - CD8-Positive T-Lymphocytes/*immunology
MH  - Cell Communication
MH  - Cytokines/metabolism
MH  - Cytotoxicity, Immunologic
MH  - Dendritic Cells/*immunology/transplantation
MH  - Humans
MH  - Immunotherapy, Adoptive/*methods
MH  - Neoplasms/immunology/*therapy
PMC - PMC6521804
OTO - NOTNLM
OT  - cDC1
OT  - cDC2
OT  - cancer immunity
OT  - crosstalk
OT  - dendritic cells
EDAT- 2019/05/31 06:00
MHDA- 2020/10/02 06:00
PMCR- 2019/01/01
CRDT- 2019/05/31 06:00
PHST- 2018/08/30 00:00 [received]
PHST- 2019/04/23 00:00 [accepted]
PHST- 2019/05/31 06:00 [entrez]
PHST- 2019/05/31 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
PHST- 2019/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2019.01014 [doi]
PST - epublish
SO  - Front Immunol. 2019 May 9;10:1014. doi: 10.3389/fimmu.2019.01014. eCollection 
      2019.